Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a pleasure to talk with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) about these research highlights from 2022.
Disclosures: Gil Melmed discloses consulting for Abbvie, Arena, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Genetech, Pfizer, Samsung Bioepis, Takeda, Shionogi, Prometheus Labs, Techlab, Fresenius Kabi, and Amgen; and receiving grant/ research support from Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
To find out more visit our gastroenterology content here.
Share this Video
Related Videos In Digestive Disorders
LIBERTY-EoE-TREET analysis looking at prior use of topical corticosteroids: Arjan Bredenoord, DDW 2023
The phase 3 LIBERTY-EoE-TREET study (NCT03633617) evaluated the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic oesophagitis. We caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the part C subgroup analysis, which investigated the effect of prior topical corticosteroid use on the efficacy of […]
Dupilumab as a therapeutic option for eosinophilic oesophagitis: Arjan Bredenoord, DDW 2023
Dupilumab is a fully human monoclonal antibody that inhibits the interleukin-4 and interleukin-13 pathways, and has been approved for the treatment of eosinophilic oesophagitis in the USA and Europe. touchIMMUNOLOGY caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the burden of eosinophilic oesophagitis, limitations of current therapeutic options, […]
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!